NEO (NeoGenomics) LT-Debt-to-Total-Asset : 0.25 (As of Jun. 2024)

View and export this data going back to 1996. Start your Free Trial

What is NeoGenomics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. NeoGenomics's long-term debt to total assests ratio for the quarter that ended in Jun. 2024 was 0.25.

NeoGenomics's long-term debt to total assets ratio declined from Jun. 2023 (0.36) to Jun. 2024 (0.25). It may suggest that NeoGenomics is progressively becoming less dependent on debt to grow their business.

NeoGenomics LT-Debt-to-Total-Asset Historical Data

The historical data trend for NeoGenomics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeoGenomics LT-Debt-to-Total-Asset Chart

NeoGenomics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.17

0.21

0.32

0.35

0.36

NeoGenomics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.36	0.36	0.36	0.37	0.25

NeoGenomics LT-Debt-to-Total-Asset Calculation

NeoGenomics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	606.069	/	1681.229
	=	0.36

NeoGenomics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (Q: Jun. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2024 )	/	Total Assets (Q: Jun. 2024 )
	=	402.871	/	1643.277
	=	0.25

NeoGenomics (NAS:NEO) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

NeoGenomics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of NeoGenomics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

NeoGenomics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » NeoGenomics Inc (NAS:NEO) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

NEO:Mexico NG9:Germany NG9:Germany

Address

9490 NeoGenomics Way, Fort Myers, FL, USA, 33912

Website

https://www.neogenomics.com

NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services.

Executives

Alicia C Olivo	officer: General Counsel	9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Lynn A. Tetrault	director	12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS FL 33913
Anthony P. Zook	director	C/O VIVUS, INC., 351 EAST EVELYN AVENUE, MOUNTAIN VIEW CA 94041
Elizabeth Floegel	director	9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Neil Gunn	director	9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Greg D Aunan	officer: Chief Accounting Officer	HMS HOLDINGS CORP., 5615 HIGH POINT DRIVE, IRVING TX 75038
Jeffrey Scott Sherman	officer: Chief Financial Officer	103 POWELL COURT, SUITE 200, BRENTWOOD TN 37027
Melody Harris	officer: President, Enterprise Ops	4801 WEST BYRON PLACE, DENVER CO 80211
Warren Stone	officer: President, Clinical Services	9490 NEOGENOMICS WAY, FORT MYERS FL 33912
David Brian Perez	director	12100 6TH AVENUE, LAKEWOOD CO 80228
Christopher M Smith	officer: Chief Executive Officer	125 CONSTITUTION DRIVE, MENLO PARK CA 94025
Shashikant Kulkarni	officer: President of Lab Operations	9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Vishal Sikri	officer: President and CCO, Inivata	9490 NEOGENOMICS WAY, FORT MYERS FL 33912
David Sholehvar	officer: President, Clinical Services	9490 NEOGENOMICS WAY, FORT MYERS FL 33912
William Bonello	officer: VP, Investor Relations	12780 WESTLINKS DRIVE, FORT MYERS FL 33913